Top Page
Memphasys Ltd
(Sydney:MEM)
Memphasys Ltd (MEM) vs. iShares MSCI Australia ETF (EWA)
Memphasys Ltd Business Overview & Revenue Model
Memphasys Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 526.92K | 526.92K | 60.00K | 15.37K | 27.15K | 211.48K |
| Gross Profit | 431.06K | 431.06K | -1.57M | -824.86K | -922.60K | -48.00K |
| EBITDA | -2.57M | -2.57M | -4.24M | -2.36M | -1.39M | -1.14M |
| Net Income | -4.94M | -4.94M | -4.44M | -3.40M | -2.08M | -1.49M |
Balance Sheet | ||||||
| Total Assets | 11.02M | 11.02M | 12.43M | 14.67M | 14.12M | 14.58M |
| Cash, Cash Equivalents and Short-Term Investments | 298.30K | 298.30K | 277.80K | 637.83K | 311.83K | 2.00M |
| Total Debt | 5.11M | 5.11M | 4.81M | 6.37M | 5.56M | 5.36M |
| Total Liabilities | 5.65M | 5.65M | 5.59M | 7.28M | 6.47M | 5.97M |
| Stockholders Equity | 5.37M | 5.37M | 6.84M | 7.38M | 7.65M | 8.61M |
Cash Flow | ||||||
| Free Cash Flow | -2.41M | -2.41M | -3.87M | -3.23M | -2.61M | -2.96M |
| Operating Cash Flow | -2.41M | -2.41M | -3.23M | -1.41M | 311.82K | 47.25K |
| Investing Cash Flow | -673.28K | -673.28K | -711.05K | -1.98M | -3.08M | -3.00M |
| Financing Cash Flow | 3.15M | 3.15M | 3.54M | 3.75M | 1.03M | 2.99M |
Memphasys Ltd Peers Comparison
Memphasys Ltd Corporate Events
Memphasys Limited announced changes in its board of directors, with Mr. Mathew Watkins appointed and Mr. David Ali ceasing as directors. The company acknowledged an administrative oversight in the timely filing of director interest notices but assured that current compliance arrangements are adequate. These changes are not expected to impact the company’s operations or compliance with ASX listing rules.
Memphasys Limited has secured a repeat order for 200 Felix ™ cartridges from the Nishitan ART Clinic Group in Japan, highlighting the growing adoption of its technology in the world’s largest IVF market. This order marks a significant step in Memphasys’ strategy to expand its direct commercial footprint in Japan, leveraging the country’s substantial self-pay IVF segment to drive revenue growth and enhance its market position.
Memphasys Ltd has announced the details for its 2025 Annual General Meeting (AGM), which will be held physically in Sydney. The company is adapting to modern communication methods by providing meeting materials online and encouraging electronic voting and communication, reflecting a shift towards more digital engagement with shareholders.
Memphasys Limited has announced several board changes as it pivots towards the commercialisation of its Felix ™ System. Dr. David Ali will step down as Executive Director to focus on his role as CEO, emphasizing operational execution as the company prepares for a global market rollout. Marjan Mikel has been appointed Chair of Commercialisation to oversee strategy and market expansion, while Mathew Watkins joins as an Independent Non-Executive Director, bringing extensive ASX experience to support the company’s growth and compliance efforts. These changes are aimed at strengthening Memphasys’ ability to execute its commercialisation plan, including the European launch post CE-Mark approval.
Memphasys Limited has dispatched its prospectus for a 1-for-6 pro-rata Non-Renounceable Entitlement Issue, aiming to raise approximately $1.12 million. The funds will support the commercialisation of the Felix™ System, including regulatory approvals for the European market, and provide working capital for corporate purposes. This initiative is expected to enhance Memphasys’s market position in the fertility treatment industry by advancing the adoption and production of its Felix™ System.
Memphasys Limited has announced a change in its company secretary, with Mr. Andrew Metcalfe concluding his role and Mr. Stefan Ross stepping in as the new Company Secretary effective 8 October 2025. Mr. Ross brings over 17 years of experience in governance and compliance, which will be instrumental as Memphasys progresses the commercialisation of its Felix™ System, aiming to establish it as a global standard in sperm selection.
Memphasys Ltd has announced an update regarding the proposed issue of securities, specifically a new class of options that will be unquoted. This update is part of their ongoing efforts to manage securities and align with ASX Listing Rules, potentially impacting their market operations and investor relations.
Memphasys Ltd has announced a proposed issue of securities, with a total of 118,564,120 securities to be issued, including various options and ordinary fully paid shares. This strategic move is expected to enhance the company’s capital structure, potentially impacting its market positioning and providing opportunities for growth and expansion in the reproductive biotechnology industry.
Memphasys Ltd has announced a proposed issue of securities, including 93,379,088 NRRI options and 373,516,350 ordinary fully paid shares, as part of a standard pro rata issue. This move is expected to impact the company’s financial structure and may influence its market positioning by potentially increasing capital for further development and expansion, thereby affecting stakeholders’ interests.
Memphasys Ltd has announced a pro-rata non-renounceable entitlement offer, allowing shareholders to acquire 1 share for every 6 shares held at $0.003 per share, along with 1 free new option for every 4 shares applied for. The company aims to raise approximately $1,120,549 through this offer, which includes secondary offers of new options to placement participants and Lynx. This move is part of Memphasys’ strategy to strengthen its financial position and potentially enhance shareholder value, although the securities offered are considered highly speculative.
Memphasys Limited has completed a placement of 257,500,000 ordinary shares at $0.003 per share, as announced on 1 October 2025. The company has issued these shares without disclosure under Part 6D.2 of the Corporations Act and has confirmed compliance with relevant provisions of the Corporations Act, ensuring transparency and adherence to regulatory standards.
Memphasys Ltd announced the application for quotation of 257,500,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to impact the company’s market presence by potentially increasing liquidity and investor interest.
Memphasys Ltd, a company listed on the Australian Securities Exchange (ASX), has released an investor presentation focused on the commercialization of its product, Felix. The presentation outlines indicative timelines for product development and commercialization activities, emphasizing that these timelines are based on current estimates and may change. The company advises investors to seek appropriate financial advice before making any investment decisions and disclaims any responsibility for the information provided in the presentation.
Memphasys Ltd has announced a proposed issue of securities, planning to issue up to 297,500,000 ordinary fully paid shares and 74,375,000 placement options. This move is aimed at raising capital to support the company’s operations and strategic initiatives, potentially enhancing its market position and providing value to stakeholders.
Memphasys Limited has successfully completed a placement raising approximately $0.84 million to accelerate the commercialisation and manufacturing scale-up of its Felix™ technology. The company has also reduced its operational costs by 40%, redirecting funds towards manufacturing and inventory build-up to improve gross margins. This strategic pivot has garnered strong investor support, emphasizing the company’s focus on immediate revenue generation and cost efficiency. The raised funds will be used to fulfill existing contracts, progress negotiations in new markets, and support regulatory processes, positioning Memphasys for significant revenue growth in FY2026.
Memphasys Limited, listed on the Australian Securities Exchange under the code MEM, has requested a trading halt pending an announcement regarding a proposed capital raising. The halt is intended to ensure an orderly market in the company’s securities. The trading halt is expected to last until Memphasys makes the announcement, anticipated before the commencement of trading on Monday, 22 September 2025.
Memphasys Limited has announced a significant upgrade to its contract with International Technical Legacy (ITL), increasing the contract value to A$390,000 and expanding its territory to include Turkey, a key IVF market in the EU. This expansion marks Memphasys’ first contracted revenues in the EU, contingent on CE Mark approval, and is part of a broader strategy to establish a scalable revenue model and strengthen its presence in the European IVF market.
Memphasys Limited announced the resignation of Mr. Paul Wright as Non-Executive Director, who has been with the company since March 2020, contributing significantly to its progress. The company remains focused on the commercialisation of its Felix™ technology in early access markets, supported by a strong board with expertise in technology, commercialisation, and reproductive health, ensuring continued growth and strategic development.
Memphasys Limited has signed a transformative five-year exclusive distribution agreement with International Technical Legacy (ITL) for its Felix™ sperm preparation system across 15 countries in the Middle East and North Africa. This partnership, which includes an initial order valued at A$325,000 contingent on CE Mark approval, positions Memphasys to access a market with approximately 140,000 IVF cycles annually. The agreement ensures rapid adoption through ITL’s established presence and expertise, and it includes provisions for future reproductive technologies. Memphasys is also pursuing similar agreements in other regions, aiming to generate immediate cash flows and diversify revenue streams, thereby de-risking its broader rollout strategy.
Memphasys Limited reported a significant decline in its financial performance for the year ending June 30, 2025, with revenue from continuing ordinary activities decreasing by 94% and a net loss attributable to members increasing by 11% to $4.942 million. Despite these challenges, the company maintains its position in the biotechnology sector, although the financial results may impact stakeholder confidence and necessitate strategic adjustments to address the declining financial metrics.
Memphasys Ltd has announced the results of its General Meeting held on August 8, 2025. The meeting included the ratification of prior issues of shares and options under the May 2025 Placement and the appointment of an auditor, all of which were carried with significant majorities. This outcome reflects strong shareholder support for the company’s recent financial strategies and governance decisions.
Memphasys Ltd, listed on the Australian Securities Exchange under the symbol ASX:MEM, has released a presentation outlining high-impact, high-potential opportunities in global growth markets. The presentation, approved by the company’s board, provides indicative timelines for product development and commercialization activities, emphasizing the company’s strategic focus on expanding its market presence. However, it includes a disclaimer noting that the information should not be solely relied upon for investment decisions and highlights that timelines are subject to change.
Memphasys Limited has made significant strides in its operations during the June 2025 quarter, notably with the completion of the CE Mark submission for its Felix™ system, which is expected to open access to Europe’s IVF market. The company has also pivoted its commercial strategy to focus on direct sales in low-regulatory markets such as Japan, New Zealand, UAE, and Canada, achieving repeat sales in Japan. Additionally, Memphasys has advanced its RoXsta™ platform, which has shown potential in various applications, including fertility and sports medicine, and is preparing for large-scale studies. The company is also reviewing its manufacturing and supply chain processes to optimize costs and ensure regulatory compliance, positioning itself for efficient global scaling.